Metastatic prostate cancer incidence and prostate-specific antigen testing: New insights from the European Randomized Study of Screening for Prostate Cancer

European Urology

Volumn 68, Issue 5, 2015, Pages 885-890

  Buzzoni, Carlotta ^a   Auvinen, Anssi ^b   Roobol, Monique J ^c   Carlsson, Sigrid ^d,e   Moss, Sue M ^f   Puliti, Donella ^a   De Koning, Harry J ^c   Bangma, Chris H ^c   Denis, Louis J ^g   Kwiatkowski, Maciej ^h,i   Lujan, Marcos ^j   Nelen, Vera ^k   Paez, Alvaro ^l   Randazzo, Marco ^h,m   Rebillard, Xavier ⁿ   Tammela, Teuvo L J ^o   Villers, Arnauld ^p   Hugosson, Jonas ^d   Schröder, Fritz H ^c   Zappa, Marco ^a  

^a CANCER RESEARCH AND PREVENTION INSTITUTE ISPO   (Italy)

^b TAMPERE UNIVERSITY OF TECHNOLOGY   (Finland)

^c ERASMUS MEDICAL CENTER   (Netherlands)

^d UNIVERSITY OF GOTHENBURG   (Sweden)

^e MEMORIAL SLOAN KETTERING CANCER CENTER   (United States)

^f QUEEN MARY UNIVERSITY OF LONDON   (United Kingdom)

^g Oncology Centre of Antwerp   (Belgium)

^h CANTONAL HOSPITAL AARAU   (Switzerland)

ⁱ Academic Hospital Braunschweig   (Germany)

^j HOSPITAL INFANTA CRISTINA   (Spain)

^k Provinciaal Instituut voor Hygiene   (Belgium)

^l HOSPITAL UNIVERSITARIO DE FUENLABRADA   (Spain)

^m UNIVERSITY HOSPITAL ZURICH   (Switzerland)

ⁿ Clinique Beausoleil   (France)

^o TAMPERE UNIVERSITY HOSPITAL   (Finland)

^p UNIV LILLE   (France)

more..

Author keywords

Metastatic cancer incidence; Mortality reduction; Prostate screening; PSA

Indexed keywords

PROSTATE SPECIFIC ANTIGEN; KALLIKREIN; KALLIKREIN-RELATED PEPTIDASE 3, HUMAN;

ADULT; AGED; ARTICLE; CANCER INCIDENCE; CANCER MORTALITY; CANCER REGISTRY; CANCER RISK; CANCER SCREENING; CANCER STAGING; COMPARATIVE STUDY; CONTROLLED STUDY; EUROPEAN; FOLLOW UP; GLEASON SCORE; HUMAN; MAJOR CLINICAL STUDY; MALE; METASTATIC PROSTATE CANCER; MULTICENTER STUDY; OUTCOME ASSESSMENT; PRIORITY JOURNAL; PROSTATE CANCER; RANDOMIZED CONTROLLED TRIAL; SENSITIVITY ANALYSIS; BLOOD; CANCER GRADING; CLINICAL TRIAL; EARLY CANCER DIAGNOSIS; INCIDENCE; METASTASIS; MIDDLE AGED; PATHOLOGY; PROCEDURES; PROSTATIC NEOPLASMS; REGRESSION ANALYSIS; RISK ASSESSMENT;

AGED; EARLY DETECTION OF CANCER; HUMANS; INCIDENCE; KALLIKREINS; MALE; MIDDLE AGED; NEOPLASM GRADING; NEOPLASM METASTASIS; NEOPLASM STAGING; PROSTATE-SPECIFIC ANTIGEN; PROSTATIC NEOPLASMS; REGRESSION ANALYSIS; RISK ASSESSMENT;

EID: 84942983796     PISSN: 03022838     EISSN: 18737560     Source Type: Journal    
DOI: 10.1016/j.eururo.2015.02.042     Document Type: Article

References (19)

1. F.H. Schröder, J. Hugosson, M.J. Roobol, and et al. Screening and prostate cancer mortality: results of the European Randomised Study of Screening for Prostate Cancer (ERSPC) at 13 years of follow-up Lancet 384 2014 2027 2035
2. A.B. Miller New data on prostate-cancer mortality after PSA screening N Engl J Med 366 2012 1047 1048
3. I.E. Haines, and G.L. Gabor Miklos Prostate-specific antigen screening trials and prostate cancer deaths: the androgen deprivation connection J Natl Cancer Inst 105 2013 1534 1539
4. S. Carlsson, M.J. Roobol, F.H. Schröder, J. Hugosson, and A. Auvinen Re: Prostate-specific antigen screening trials and prostate cancer deaths: the androgen deprivation connection J Natl Cancer Inst 106 2014 dju079
5. T. Wolters, M.J. Roobol, E.W. Steyerberg, and et al. The effect of study arm on prostate cancer treatment in the large screening trial ERSPC Int J Cancer 126 2010 2387 2393
6. P.J. Van Leeuwen, R. Kranse, T. Hakulinen, and et al. Impacts of a population-based prostate cancer screening programme on excess all-mortality rates in men with prostate cancer: a randomized controlled trial J Med Screen 20 2013 33 38
7. R. Kranse, P.J. van Leeuwen, T. Hakulinen, and et al. Excess all-cause mortality in the evaluation of a screening trial to account for selective participation J Med Screen 20 2013 39 45
8. M. Zappa, D. Puliti, J. Hugosson, and et al. A different method of evaluation of the ERSPC trial confirms that prostate-specific antigen testing has a significant impact on prostate cancer mortality Eur Urol 66 2014 401 403
9. P. Autier, C. Héry, J. Haukka, M. Boniol, and G. Byrnes Advanced breast cancer and breast cancer mortality in randomized controlled trials on mammography screening J Clin Oncol 27 2009 5919 5923
10. F.H. Schröder, J. Hugosson, S. Carlsson, and et al. Screening for prostate cancer decreases the risk of developing metastatic disease: findings from the European Randomized Study of Screening for Prostate Cancer (ERSPC) Eur Urol 62 2012 745 752
11. F.H. Schröder, L.J. Denis, M.J. Roobol, and et al. The story of the European Randomized Study of Screening for Prostate Cancer BJU Int 92 Suppl 2 2003 1 13
12. F.H. Schröder, J. Hugosson, M.J. Roobol, and et al. Screening and prostate-cancer mortality in a randomized European study N Engl J Med 360 2009 1320 1328
13. H.J. De Koning, J. Blom, J.W. Merkelbach, and et al. Determining the cause of death in randomized screening trial(s) for prostate cancer BJU Int 92 2003 71 78
14. F.L. Greene, D.L. Page, I.D. Fleming, and et al. The AJCC cancer staging atlas ed. 6. 2002 American Joint Committee on Cancer Chicago, IL
15. S. Van Buuren, and C.G.M. Oudshoorn Multivariate imputation by chained equations: MICE V1.0 User's manual. TNO Report PG/VGZ/00.038. Leiden 2000 TNO Preventie en Gezondheid The Netherlands
16. D.B. Rubin Inference and missing data Biometrika 63 1976 581 592
17. I.R. White, P. Royston, and A.M. Wood Multiple imputation using chained equations: issues and guidance for practice Stat Med 30 2001 377 399
18. D.B. Rubin Multiple imputation for nonresponse in surveys 1987 John Wiley & Sons New York, NY
19. F.H. Schröder, J. Hugosson, M.J. Roobol, and et al. Prostate-cancer mortality at 11 years of follow-up N Engl J Med 366 2012 981 990